Cargando…

Resorcinol-, catechol- and saligenin-based bronchodilating β2-agonists as inhibitors of human cholinesterase activity

We investigated the influence of bronchodilating β2-agonists on the activity of human acetylcholinesterase (AChE) and usual, atypical and fluoride-resistant butyrylcholinesterase (BChE). We determined the inhibition potency of racemate and enantiomers of fenoterol as a resorcinol derivative, isoetha...

Descripción completa

Detalles Bibliográficos
Autores principales: Bosak, Anita, Knežević, Anamarija, Gazić Smilović, Ivana, Šinko, Goran, Kovarik, Zrinka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445159/
https://www.ncbi.nlm.nih.gov/pubmed/28573890
http://dx.doi.org/10.1080/14756366.2017.1326109
_version_ 1783408152779161600
author Bosak, Anita
Knežević, Anamarija
Gazić Smilović, Ivana
Šinko, Goran
Kovarik, Zrinka
author_facet Bosak, Anita
Knežević, Anamarija
Gazić Smilović, Ivana
Šinko, Goran
Kovarik, Zrinka
author_sort Bosak, Anita
collection PubMed
description We investigated the influence of bronchodilating β2-agonists on the activity of human acetylcholinesterase (AChE) and usual, atypical and fluoride-resistant butyrylcholinesterase (BChE). We determined the inhibition potency of racemate and enantiomers of fenoterol as a resorcinol derivative, isoetharine and epinephrine as catechol derivatives and salbutamol and salmeterol as saligenin derivatives. All of the tested compounds reversibly inhibited cholinesterases with K(i) constants ranging from 9.4 μM to 6.4 mM and had the highest inhibition potency towards usual BChE, but generally none of the cholinesterases displayed any stereoselectivity. Kinetic and docking results revealed that the inhibition potency of the studied compounds could be related to the size of the hydroxyaminoethyl chain on the benzene ring. The additional π–π interaction of salmeterol’s benzene ring and Trp286 and hydrogen bond with His447 probably enhanced inhibition by salmeterol which was singled out as the most potent inhibitor of all the cholinesterases.
format Online
Article
Text
id pubmed-6445159
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-64451592019-04-09 Resorcinol-, catechol- and saligenin-based bronchodilating β2-agonists as inhibitors of human cholinesterase activity Bosak, Anita Knežević, Anamarija Gazić Smilović, Ivana Šinko, Goran Kovarik, Zrinka J Enzyme Inhib Med Chem Research Paper We investigated the influence of bronchodilating β2-agonists on the activity of human acetylcholinesterase (AChE) and usual, atypical and fluoride-resistant butyrylcholinesterase (BChE). We determined the inhibition potency of racemate and enantiomers of fenoterol as a resorcinol derivative, isoetharine and epinephrine as catechol derivatives and salbutamol and salmeterol as saligenin derivatives. All of the tested compounds reversibly inhibited cholinesterases with K(i) constants ranging from 9.4 μM to 6.4 mM and had the highest inhibition potency towards usual BChE, but generally none of the cholinesterases displayed any stereoselectivity. Kinetic and docking results revealed that the inhibition potency of the studied compounds could be related to the size of the hydroxyaminoethyl chain on the benzene ring. The additional π–π interaction of salmeterol’s benzene ring and Trp286 and hydrogen bond with His447 probably enhanced inhibition by salmeterol which was singled out as the most potent inhibitor of all the cholinesterases. Taylor & Francis 2017-06-02 /pmc/articles/PMC6445159/ /pubmed/28573890 http://dx.doi.org/10.1080/14756366.2017.1326109 Text en © 2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Paper
Bosak, Anita
Knežević, Anamarija
Gazić Smilović, Ivana
Šinko, Goran
Kovarik, Zrinka
Resorcinol-, catechol- and saligenin-based bronchodilating β2-agonists as inhibitors of human cholinesterase activity
title Resorcinol-, catechol- and saligenin-based bronchodilating β2-agonists as inhibitors of human cholinesterase activity
title_full Resorcinol-, catechol- and saligenin-based bronchodilating β2-agonists as inhibitors of human cholinesterase activity
title_fullStr Resorcinol-, catechol- and saligenin-based bronchodilating β2-agonists as inhibitors of human cholinesterase activity
title_full_unstemmed Resorcinol-, catechol- and saligenin-based bronchodilating β2-agonists as inhibitors of human cholinesterase activity
title_short Resorcinol-, catechol- and saligenin-based bronchodilating β2-agonists as inhibitors of human cholinesterase activity
title_sort resorcinol-, catechol- and saligenin-based bronchodilating β2-agonists as inhibitors of human cholinesterase activity
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445159/
https://www.ncbi.nlm.nih.gov/pubmed/28573890
http://dx.doi.org/10.1080/14756366.2017.1326109
work_keys_str_mv AT bosakanita resorcinolcatecholandsaligeninbasedbronchodilatingb2agonistsasinhibitorsofhumancholinesteraseactivity
AT knezevicanamarija resorcinolcatecholandsaligeninbasedbronchodilatingb2agonistsasinhibitorsofhumancholinesteraseactivity
AT gazicsmilovicivana resorcinolcatecholandsaligeninbasedbronchodilatingb2agonistsasinhibitorsofhumancholinesteraseactivity
AT sinkogoran resorcinolcatecholandsaligeninbasedbronchodilatingb2agonistsasinhibitorsofhumancholinesteraseactivity
AT kovarikzrinka resorcinolcatecholandsaligeninbasedbronchodilatingb2agonistsasinhibitorsofhumancholinesteraseactivity